News
Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19
Partnership Leverages TScan’s Proprietary High-throughput TCR/Target Discovery Platform and Poseida’s Proprietary Allogeneic T Cell Approach to Advance Potential TCR-T Treatments
SAN DIEGO and WALTHAM, Mass., Oct. 21, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, and TScan Therapeutics, Inc., a biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies in oncology, today announced a research collaboration and license agreement to explore developing TCR-T cell therapies for the treatment of COVID-19. Poseida’s allogeneic T cell platform will be used in combination with TScan’s discovered immunodominant epitopes and TCR sequences for the development and commercialization of allogeneic TCR-T cell therapies.